Cargando…

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in unimmunized infected (group 1), immunised and boosted (group 2) and infected immunised and boosted (group 3) adult individuals. Our observations support the rapid administration of a booster vaccine dose to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ariën, Kevin K., Heyndrickx, Leo, Michiels, Johan, Vereecken, Katleen, Van Lent, Kurt, Coppens, Sandra, Willems, Betty, Pannus, Pieter, Martens, Geert A., Van Esbroeck, Marjan, Goossens, Maria E., Marchant, Arnaud, Bartholomeeusen, Koen, Desombere, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904765/ https://www.ncbi.nlm.nih.gov/pubmed/35260578 http://dx.doi.org/10.1038/s41541-022-00459-z

Ejemplares similares

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
por: Canti, Lorenzo, et al.
Publicado: (2022)

Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Canti, Lorenzo, et al.
Publicado: (2021)

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
por: Pannus, Pieter, et al.
Publicado: (2022)

Chikungunya Virus’ High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells
por: De Caluwé, Lien, et al.
Publicado: (2022)

Validation of a Reporter Cell Line for Flavivirus Inhibition Assays
por: Rezende, Tatiana M. T., et al.
Publicado: (2023)

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
por: Peeters, M., et al.
Publicado: (2021)

The CD147 Protein Complex Is Involved in Entry of Chikungunya Virus and Related Alphaviruses in Human Cells
por: De Caluwé, Lien, et al.
Publicado: (2021)

Dynamics of the Magnitude, Breadth and Depth of the Antibody Response at Epitope Level Following Dengue Infection
por: Falconi-Agapito, Francesca, et al.
Publicado: (2021)

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors
por: Konnova, Angelina, et al.
Publicado: (2022)

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay
por: Mariën, Joachim, et al.
Publicado: (2021)

MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency
por: Grupping, Katrijn, et al.
Publicado: (2012)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

HJ16 induced resistant virus displays rare natural mutation highlighting the conserved nature of this new CD4bs epitope
por: Balla-Jhagihoorsingh, Sunita S, et al.
Publicado: (2011)

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
por: Kemlin, Delphine, et al.
Publicado: (2023)

Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients
por: Brandolini, Martina, et al.
Publicado: (2023)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults
por: Pannus, Pieter, et al.
Publicado: (2023)

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
por: Baron, Frédéric, et al.
Publicado: (2022)

Characterization of Neutralizing Profiles in HIV-1 Infected Patients from whom the HJ16, HGN194 and HK20 mAbs were Obtained
por: Balla-Jhagjhoorsingh, Sunita S., et al.
Publicado: (2011)

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
por: Cheung, Ka Shing, et al.
Publicado: (2022)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.
por: Goossens, Maria E., et al.
Publicado: (2021)

The N276 Glycosylation Site Is Required for HIV-1 Neutralization by the CD4 Binding Site Specific HJ16 Monoclonal Antibody
por: Balla-Jhagjhoorsingh, Sunita S., et al.
Publicado: (2013)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort
por: Šošić, Lara, et al.
Publicado: (2021)

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
por: Basile, Kerri, et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia
por: Huits, Ralph, et al.
Publicado: (2018)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
por: Wall, Emma C, et al.
Publicado: (2021)

Autochthonous Cases of Tick-Borne Encephalitis, Belgium, 2020
por: Stoefs, Anke, et al.
Publicado: (2021)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study
por: Bruel, Timothée, et al.
Publicado: (2022)

Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2
por: Mariën, Joachim, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Genome Mining Uncovers NRPS and PKS Clusters in Rothia dentocariosa with Inhibitory Activity against Neisseria Species
por: Akomoneh, Elvis Achondou, et al.
Publicado: (2023)

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
por: García-Pérez, Javier, et al.
Publicado: (2022)

Zika virus in semen: a prospective cohort study of symptomatic travellers returning to Belgium
por: Huits, Ralph, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_co4mshq0bre2pq33gks1okhfdv